CAL 102
Alternative Names: CAL-102Latest Information Update: 05 Feb 2024
At a glance
- Originator Calluna Pharma
- Class Cardiovascular therapies; Monoclonal antibodies
- Mechanism of Action Phosphatidylcholine inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Myocardial reperfusion injury